AEterna Zentaris Breakout on FDA Catalysts

spacer
spacer
spacerBreaking News and Insider ScoopsApril 21, 2011
spacer
spacer
spacer
AEterna Zentaris Placed On Breakout Alert Ahead of FDA Catalysts
(NASDAQ:AEZS)


AEterna Zentaris has three critical FDA catalysts coming up in the 2nd half of the year which could propel it to new highs:
1) Perifosine (KRX-0401) Pivotal Phase 3 study completion and top-line results, an inhibitor anti-cancer agent for relapsed / refractory multiple myeloma.
2) SOLOREL, treatment of maci-morelin (AEZS-130), announced SPA agreement and expects results during 1st half 2011 to support NDA filing by end of year.
3) AEZS-108, a LHRH agonist linked doxorubicin conjugate, for endometrial cancer, expects to begin phase 3 pivotal study in mid 2011.
Technical Analysis:
http://chart.ly/uploads/large_8wgyu72.png?1303395241


spacer

Full chart: http://chart.ly/uploads/large_8wgyu72.png?1303395241

We will have a report coming out this weekend on potential target market, price target, financial conditions and more.


spacer
spacer
spacer
spacerLatest Updates

spacer
  • $AEZS looks to breakout to new 52-week highs
  • $AVNR partnership may be close, expect stellar earnings report
spacer
spacer
spacer
spacer
© Copyright 2010 MiV Investments Inc., TheMarketFinancial.com
spacer

1 comment:

nclaeys said...

Weekends over, no report. Awesome, very reliable.